Ascendis Pharma CEO tight-lipped on potential assault on Novo Nordisk's mother lode
Jan Møller MIkkelsen, CEO of Ascendis Pharma, dodged a question at a conference about whether he is currently drawing up battle plans targeting the obesity and diabetes market.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
The prospects of winning even a thin slice of the rapidly growing – and extremely lucrative – market for GLP-1 drugs for the treatment of type 2 diabetes, obesity, and more should appeal to most pharma leaders.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk ready to go toe to toe with Ascendis
For subscribers
